The effects of nifedipine on arterial oxygenation and hemodynamics were studied at rest and during bicycle exercise in 12 men (mean age 55 years, range 41 to 67) with stable exertional angina. The study was conducted double-blind on 2 days, 1 week apart, using a placebocontrolled crossover design. On each day, measurements at rest were made before and 20 minutes after 20 mg sublingual nifedipine or placebo and were followed by measurements made during exercise. Compared with placebo, nifedipine reduced mean arterial pressure, systemic vascular resistance and pulmonary vascular resistance, and increased heart rate and cardiac output at rest and during exercise. It did not alter mean pulmonary artery or pulmonary artery wedgepressures at rest, but decreased them during exercise.
The effects of nifedipine on arterial oxygenation and hemodynamics were studied at rest and during bicycle exercise in 12 men (mean age 55 years, range 41 to 67) with stable exertional angina. The study was conducted double-blind on 2 days, 1 week apart, using a placebocontrolled crossover design. On each day, measurements at rest were made before and 20 minutes after 20 mg sublingual nifedipine or placebo and were followed by measurements made during exercise. Compared with placebo, nifedipine reduced mean arterial pressure, systemic vascular resistance and pulmonary vascular resistance, and increased heart rate and cardiac output at rest and during exercise. It did not alter mean pulmonary artery or pulmonary artery wedgepressures at rest, but decreased them during exercise.
Nifedipine decreased arterial oxygen tension (Paoj) from 96 ± 10 to 90 ± 13 min Hg (p < 0.05) at rest and from 99 ± 11 to 92 ± 12 mm Hg (p < 0.005) at subNifedipine is used in the treatment of a wide range of cardiovascular disorders (1) (2) (3) (4) (5) (6) (7) (8) , and is a potent dilator of systemic, coronary and pulmonary arterioles (9, 10) . Pulmonary vasodilators have been shown to increase ventilation-perfusion imbalance in the lungs and decrease arterial oxygen tension (Pao-) (11) (12) (13) (14) (15) . The effects of nifedipine on ventilation-perfusion imbalance and Pao, have been reported at rest in normal subjects (16) and in patients with respiratory failure (10) and primary pulmonary hypertension (17) . However, these effects have not been reported in patients with exertional angina, either at rest or during exercise. An un-These findings suggest that nifedipine reduced Pao, at rest and submaximal exercise by increasing ventilation-perfusion imbalance in the lungs, probably as a result of pulmonary vasodilation and increase in cardiac output. No correlation was found between the reduction in rest Pao, and pulmonary vascular resistance, suggesting that other factors were involved.
(J Am Call CardioI1986; 8:1461-6) derstanding of these actions is important, because a decrease in arterial oxygenation may increase myocardial ischemia in patients with coronary artery disease. This was demonstrated in a recent study (18) in which a small reduction in arterial oxygen saturation (Sao2) in patients with angina increased ST segment depression during exercise. The aims of this study were to measure the effects of 20 mg sublingual nifedipine on arterial and mixed venous blood gases at rest and during exercise in patients with exertional angina, and to relate these changes to systemic and pulmonary hemodynamics.
Methods
Study patients. Twelve men (mean age 55 years, range 41 to 67) with stable exertional angina (New York Heart Association functional class II or III) of at least 3 months' duration were studied. All patients had a positive exercise test (at least I mm flat or downsloping ST segment depres-0735-1091/86/$3.50 NIFED1P1NE AND ARTERIAL OX YGENATION JACe Vol. 8, No, 6 December 1986:1461 -6 sion at 80 ms from the J point) with the development of typical angina . Significant coronary artery disease (~70% diameter stenosis in at least one major coronary artery) was documented in the eight patients who underwent cardiac catheterization. Six patients had previous myocardial infarction , but none were in cardiac failure . No patient had arterial hypertension, valvular heart disease or lung disease.
Study design. The study was approved by the Hospital Ethics Review Committee, and informed written consent was obtained from all patients .
Before entry into the study, all patients were familiarized with the exercise protocol and study equipment. The study was placebo controlled, and was conducted double-blind on 2 days, I week apart. All antianginal medications were stopped 72 hours before each of the 2 study days, except oral ntirates, which were stopped on the days of the study.
On each day , the patients were studied in the morning in the fasting state without premedication. Intravascular catheters were first inserted, and at least 30 minutes later, control rest measurements were made . Either two to 109 nifedipine capsules or two placebo capsules were given sublingually, and rest measurements were repeated after 20 minutes. Symptom-limited graded bicycle exercise was then performed. The order of drug admini stration was randomized so that on the first day, half of the patients received placebo and the other half received nifedipine. On the second day , all patients received the alternative treatment.
Hemodynamics. A Swan-Ganz thermodilution catheter and a radial artery cannula ( 17G Teflon Dwellcath) were inserted percutaneously under local anesthesia. At rest and exercise, measurements were made with patients seated in a semiupright (45°) posture on a bicycle ergometer (Atomic Products Corporation). Phasic and mean systemic arterial, pulmonary artery, pulmonary artery wedge and right atrial pressure s were measured using Bell and Howell 4-327-1 transducers, and recorded on an Electronics for Medicine VR 12 recorder. The zero reference level was chosen at the fourth intercostal space in the midaxillary line. Cardiac output was measured by thermodilution using 10 ml boluses of ice-cooled 5% dextrose in water injectate , and the values were calculated by an Instrumentation Laboratories Computer (model 701) . Systemic and pulmonary vascular resistances were calculated using standard formulas (\ 9).
Rest studies. After hemodynamic measurements had stabilized, rest measurements were made over 6 minutes. Intravascular pressures were continuously recorded. A CM s electrocardiographic precordial lead was continuously monitored, and a 12 lead electrocardiogram was recorded every minute . Six cardiac output measurements were made and the values averaged. Blood (2 to 5 ml) was anaerobically withdrawn simulataneously from the radial and pulmonary arteries for analysis of blood gases, that is, arterial oxygen tension (Pao-), arterial oxygen saturation (Sao-), arterial carbon dioxide tension (Paco-), mixed venous oxygen tension (Pvo-), mixed venous oxygen saturation (Svo-), mixed venous carbon dioxide tension (Pvco-) and pH, using a Corning 175 Blood Gas Analyzer.
Exercise studies. Bicycle exercise was commenced at individually predetermined work loads based on results of a prior exercise test, so that all patients developed angina within 6 minutes of exercise. Work loads were controlled by an electronically braked ergometer (Siemens-Elema) and were increased by 15 W every 3 minutes until exercise was stopped by symptoms . The CM s electrocardiographic lead was continuously monitored , and a 12 lead electrocardiogram was recorded at I minute intervals. Intravascular pressures were continuously recorded . In the last 2 minutes of each work load level, three or four cardiac output measurements were made; 2 to 5 ml of blood was simultaneously withdrawn from the radial and pulmonary arteries at the end of each work load level for the analysis of blood gases, as described earlier.
Statistical analysis. The four rest measurements (two control, postplacebo and postnifedipine) were compared using a two-way analysis of variance (20) . Exercise measurements between placebo and nifedipine were compared at the same work loads using the Student's paired t test. Two work loads were chosen : the common maximal work load after placebo and nifedipine , and a submaximal work load one half the maximal load. A probability (p) value of less than 0.05 was considered statistically significant. Results are shown as mean ± I SD.
Results
Clinical response. After placebo, all patients developed angina and ST depression during exercise. Exercise was stopped because of angina in six patients and because of leg fatigue in the other six. After nifedipine, the onset of angina was abolished in four patients, delayed by at least I minute in four patients and unaltered in the other four. ST segment depression, compared at the common maximal work load after placebo and nifedipine (68.0 ± 30.3 W), was reduced from 2.5 ± 1.1 to 2.0 ± 1.0 mm (p < 0.(5).
Although nifedipine decreased angina in eight patients, five patients reported increased leg fatigue and four of them stopped exercise at a work load that was one level lower after nifedipine than after placebo. As a result, nifedipine did not alter mean exercise capacity (72.5 ± 30.6 W with placebo, 68.8 ± 28.9 W with nifedipine; p = NS) .
Rest hemodynamics. There was no difference in hemodynamic measurements between the control rest studies on both days and between the control rest studies and the rest study after placebo (Table 1) . Nifedipine decreased systemic vascular resistance and mean arterial pressure and increased heart rate and cardiac output. It decreased pulmonary vascular resistance, but did not alter mean pulmonary artery or pulmonary artery wedge pressures . 9 ± 3 10 ± 3 9 ± 2 10 ± 3 *p < 0.001, tp < 0.01 for post-nifedipine versus pre-nifedipine. There were no significant differences between pre-placebo, post-placebo and pre-nifedipine values. CO = cardiac output; HR = heart rate; MAP = mean arterial pressure: MPA = mean pulmonary artery pressure; PAW = pulmonary artery wedge pressure: PVR = pulmonary vascular resistance: SVR = systemic vascular resistance.
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Rest blood gases. There was no difference in blood gas measurements between the control rest studies on both days and between the control rest studies and the rest study after placebo ( No correlation was found (r = 0.02) between the decrease in Pao, and the decrease in pulmonary vascular resistance after nifedipine using a standard least squares regression analysis.
Exercise hemodynamics. At the submaximal (33 ± 21 W) and maximal (68 ± 30 W) work loads, nifedipine decreased systemic and pulmonary vascular resistance, mean arterial pressure and mean pulmonary artery and pulmonary artery wedge pressures and increased heart rate and cardiac output compared with placebo (Table 3) .
Exercise blood gases. During exercise after placebo, PV02 decreased progressively from 39 ± 2.7 mm Hg at rest to 31 ± 3.8 mm Hg at submaximal exercise and 27.0 ± 2.6 mm Hg at maximal exercise ( 
Discussion
Clinical response to nifedipine. All patients in this study had a history of classic stable angina, and developed chest pain with positive ST depression during exercise after placebo. Nifedipine abolished or delayed the onset of angina in 8 of the 12 patients and significantly reduced ST depression. Exercise capacity was not increased overall because exercise was performed in a strictly symptom-limited manner. Six patients stopped exercise after placebo because of leg fatigue even though moderately severe angina was also present. In addition, four patients stopped exercise at I work load level lower after nifedipine than after placebo because of increased leg fatigue.
The decrease in angina after nifedipine occurred despite reduced arterial oxygen tension (Pao-) at rest and submaximal exercise. There was no relation between the degree of reduction in Pao, at rest or submaximal exercise and the antianginal reponse to nifedipine.
Hemodynamic response to nifedipine. The hemodynamic effects of nifedipine in this study agree with those of previous reports (9, 21, 22) . At rest and exercise, nifedipine decreased systemic vascular resistance and mean arterial pressure and increased heart rate and cardiac output. These changes were due to peripheral arteriolar dilation by nifedipine and the resulting reflex hemodynamic changes. Nifedipine decreased pulmonary vascular resistance at rest, but did not decrease mean pulmonary artery pressure because of the increase in cardiac output. During exercise,
• Effects of nifedipine on rest blood gases. Nifedipine significantly reduced arterial oxygen tension (Pao-) at rest. This was not due to changes in mixed venous oxygen tension (PV02), which was increased by the higher cardiac output.
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Other possible explanations for the lower Pao2 included alveolar hypoventilation, impaired oxygen diffusion, increased ventilation-perfusion imbalance and increased intrapulmonary shunt flow (23) . Arterial carbon dioxide tension (Paco-) is an index of alveolar ventilation, and because it was unaltered, this suggested that alveolar hypoventilation did not occur. Our patients did not have interstitial lung disease and pulmonary artery wedge pressure did not change. Therefore, nifedipine is unlikely to have affected the diffusion of oxygen. These findings suggest that the reduction in Pao2 after nifedipine was due either to increased ventilation-perfusion imbalance or intrapulmonary shunt flow, or both.
Regional perfusion and ventilation in the normal lung is not homogeneous and some ventilation-perfusion imbalance normally occurs (24) , especially in the upright posture (25) . Adaptive pulmonary vasoconstriction occurs in areas with poorly ventilated alveoli, and so reduces this imbalance (24) . Nonselective pulmonary vasodilation by nifedipine may increase blood flow to poorly ventilated areas, and thereby increase venous admixture and decrease Pao-. The reduction in Pao; after nifedipine varied considerably in individual patients. There was no correlation between the decrease in pulmonary vascular resistance in individual patients and the decrease in Pao., suggesting that other important factors were involved. The degree of adaptive pulmonary vasoconstriction present before nifedipine and the degree of increase in cardiac output after nifedipine (15) could be other possible determinants of the reduction in Pao, in individual patients.
Pulmonary vasodilation by a number ofdrugs, including isoproterenol (12), aminophylline (13), nitroglycerin (14, 26, 27) and nitroprusside (15) , has been shown to increase ventilation-perfusion imbalance and decrease Pao; Table I . in various clinical situations. There have been few studies of such changes after nifedipine (10, 16) , and its effects in patients with angina are poorly defined. Naeige et al. (16) reported that 20 mg of sublingual nifedipine did not alter Pao2 in eight healthy volunteers breathing room air. A possible explanation for this difference in results is that nifedipine did not alter pulmonary vascular resistance in their study. Their volunteers were younger than our patients and so may have had less baseline ventilation-perfusion imbalance (24) . Also their measurements were made in the supine posture which may have been associated with less ventilation-perfusion imbalance than the upright or semi upright posture (25) .
In patients with exertional angina, Tirlapur and Mir (18) recently reported that nadolol decreased arterial oxygen saturation (Sao-) , and that the addition of nifedipine but not nitroglycerin to nadolol slightly increased Sao, to pre-nadolol values. However, they measured Sao; noninvasively by earoximetry and did not study nifedipine alone. In patients with chronic obstructive lung disease and acute respiratory failure, on the other hand, 20 mg of sublingual nifedipine markedly decreased pulmonary vascular resistance, and decreased Pao; from 42 to 38 mm Hg (10).
Effects of nifedipine on blood gases during exercise. The effects of nifedipine and other pulmonary vasodilators on ventilation-perfusion imbalance during exercise have not been well described. At submaximal exercise, nifedipine decreased Pao-, despite increasing PV02 because of the increased cardiac output. Nifedipine did not alter Paco-, suggesting that alveolar ventilation did not change, and reduced pulmonary artery wedge pressure. For the same reasons as were discussed in relation to conditions at rest, the reduction in Pao-, therefore, probably resulted from an increase in ventilation-perfusion imbalance or intrapulmonary shunt flow, or both.
At common maximal work loads, nifedipine did not alter Pao-, although it still decreased pulmonary vascular resistance and increased cardiac output. As nifedipine increased PV02 and SV02, it could still have increased venous admixture, but to a lesser extent than at submaximal work loads. The different effects of nifedipine on Pao2 at submaximal and maximal exercise cannot be explained from our results. It is possible that as regional ventilation and perfusion became more homogeneous during exercise (25, 28, 29) , the effects of pulmonary vasodilation in poorly ventilated regions became less prominent.
Limitations of the study. The effects of nifedipine on blood gases were interpreted by deduction in this study, and the more direct measurement of ventilation-perfusion imbalance using inert gas elimination (15) may provide additional information about pathophysiologic mechanisms underlying these changes both at rest and during exercise.
Results from single dose studies may not necessarily apply to long-term oral therapy, and further investigation of these effects during long-term nifedipine therapy is indicated.
Clinical implications. There was no obvious relation between the decrease in Pao, at rest and submaximal exercise and the antianginal response to nifedipine. In this study, the mean reduction in Pao, after nifedipine was relatively small and the reduction in Sao-, was minimal. This was probably because our patients did not have lung disease and values of Pao, were in the plateau portion of the hemoglobin-oxygen dissociation curve (30) . In patients with myocardial infarction who may have small airways disease (31 ,32) , and in patients with lung disease and increased ventilationperfusion imbalance, pulmonary vasodilation may theoretically reduce Pao, more than it did in the patients in this study. Also, in hypoxic patients who have Pao-values in the steep portion of the hemoglobin-oxygen dissociation curve, a similar reduction in Pao, may produce a much larger decrease in arterial oxygen saturation and content. Care is required when administering nifedipine to such patients.
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